Join Our Cutting-Edge Ophthalmic Research Studies
East Florida Eye Institute is at the forefront of ophthalmic research, contributing to the development of innovative treatments for eye conditions. We are excited to offer our patients the opportunity to participate in groundbreaking studies. Currently, we are welcoming participants for clinical trials in the following areas:
Diabetic Macular Edema: Examining the effectiveness of investigative eye drops (OCS-01) as a non-invasive treatment option for this condition.
Dry Macular Degeneration (Geographic Atrophy): Evaluating the potential of a one-time gene therapy treatment (JNJ-81201887), offering hope for a long-term solution to this progressive disease.
Open Angle Glaucoma or Ocular Hypertension: Exploring an experimental long-lasting implant (AGN-193408) designed to manage intraocular pressure without the burden of daily eye drops. (Enrolling soon)
Wet Macular Degeneration: Investigating a new formulation of Avastin (ONS-5010), aiming to provide improved outcomes for those affected by this condition. (Enrolling soon)
Participation in our research not only provides access to the latest treatments under development, but also contributes to the broader understanding of eye health and disease management. Join us in shaping the future of ophthalmology.
For more information on how to participate, please visit our contact page or call us directly (772) 287-9000 (option 4).
Special thanks to those who have participated in our studies.
For our valued patients that have recently participated in our clinical studies,
thank you so much for helping us with recent approvals of:
SYFOVRE FOR GEOGRAPHIC ATROPHY
IZERVAY FOR GEOGRAPHIC ATROPHY
EYLEA FOR WET MACULAR DEGENERATION AND CRVO
BEOVU FOR WET MACULAR DEGENERATION
LUCENTIS FOR DIABETIC MACULAR EDEMA
OZURDEX FOR DIABETIC MACULAR EDEMA
UPNEEQ FOR DROOPY EYELID
DUREZOL FOR USE AFTER OCULAR SURGERY
OMIDRIA FOR CATARACT SURGERY
DURYSTA FOR GLAUCOMA
ZIOPTAN FOR GLAUCOMA
SIMBRINZA FOR GLAUCOMA
TRAVATAN Z FOR GLAUCOMA
Our Clinical Research is Recognized around the world.
The many research projects currently underway for Macular Degeneration, Diabetic Eye Disease, Glaucoma, and Dry Eye Disease rapidly impact EFEI patients’ treatments and outcomes. The doctors at our vision research center in Stuart have witnessed the difference these advances can make for patients, and they strive to apply the knowledge they gain through their research to the needs of our patients every day. By combining state-of-the-art diagnostic equipment with the latest clinical advances, our patients receive cutting edge treatments, which are customized to their individual situations. The contributions of the Doctors at EFEI to the treatment of Wet Macular Degeneration and Glaucoma have been featured in the leading European Ophthalmology Journal—Euro Times, on the Macular Degeneration website: Med Page Today, MD Support , as well as on the internationally recognized medical research website Doctor’s Guide , where research was ranked as a key contribution of the year. In addition, the EFEI doctors have taught their findings to doctors from around the world at the annual meetings of the Association for Research in Vision and Ophthalmology, the American Academy of Ophthalmology, and the Asia-Pacific Academy of Ophthalmology.
We are looking to host studies for subjects with Neovascular and Dry AMD, Geographic Atrophy, Diabetic Macular Edema, Diabetic Retinopathy, Glaucoma, Dry Eye Disease, Retinal Vein Occlusion, Blepharitis, and cataracts (lens extraction and post-operative drops). For more information, please contact the research department at (772) 287-9000 (option 4).
Dr. Frenkel’s research was published in the British Journal of Ophthalmology!
Using a simple gray filter to stress patients’ eyes, ophthalmologists are able to predict visual acuity change during anti-vascular endothelial growth factor A (anti-VEGF) therapy for wet age-related macular degeneration (AMD), according to a new study.
“Now we are able to tell patients with a high degree of accuracy how they will do with anti-VEGF injections,” Dr. Ronald E.P. Frenkel, who led the study, told Reuters Health by phone. “The method is so elegant and it has incredible predictability. We couldn’t tell patients before what to expect.”
He noted that previously, the test had proved helpful in patients with dry AMD, but this is the first time anyone has tested it in patients with wet AMD.
Dr. Frenkel, of Bascom Palmer Eye Institute, Miami, and colleagues conducted the HARBOR trial, a two-year, phase 3 randomized trial of intravitreal ranibizumab (Lucentis) 0.5 or 2.0 mg monthly or as needed in wet AMD patients. A total of 1,084 patients were enrolled in the trial. Their mean age was 78.7 years and about 60 percent were women. In a Nov. 5 online paper in the British Journal of Ophthalmology, Dr. Frenkel and colleagues report change in best corrected visual acuity (BCVA) under optimal illumination over the course of the two-year study. The researchers also evaluated low-luminance visual acuity (LLVA).
Dr. Frenkel discovers a way to predict prognosis for Wet Macular Degeneration patients.
Ronald Frenkel, MD, FACS, FICS has discovered a new way to let patients with Wet Macular Degeneration know the prognosis of treatment before they start it. Dr. Frenkel has been awarded this presentation at the annual meeting of ARVO, the Association for Research in Vision and Ophthlalmology, the largest eye research meeting in the world. Dr. Frenkel served as Principal Investigator at the East Florida Eye Institute in Stuart. He headed up the portion of the colossal national multi-center HARBOR clinical trial for Wet Macular.
Degeneration treatment that discovered how to predict the patient’s prognosis and response to treatment, when one is first diagnosed with the disease. The study had 99 participating centers from across the United States and enrolled 1097 patients with newly diagnosed Wet Macular Degeneration. This will have a significant impact on patients and their families as such a prognosis does not currently exist.
Avoiding blood pressure dips helps prevent worsening of glaucoma
Current risk factors for glaucoma include high eye pressure, age, family history, and thin corneas. Through our research, we have discovered a new risk factor for glaucoma: nighttime dips in blood pressure. By having patients wear a blood pressure monitor for a 24-hour period, we have found that patients with worsening glaucoma despite “controlled” eye pressures have significant drops in their blood pressure at night. Decreased blood pressure causes decreased blood flow to the optic nerve, resulting in glaucomatous nerve damage. We work with patients’ medical doctors to diminish this risk so that glaucoma can be prevented or stabilized. (Presented at the Annual Meeting of the American Academy of Ophthalmology)
We are working diligently to put an end to vision loss from eye disease such as Macular Degeneration and Glaucoma. Through the Eye Research Foundation, we will continue to provide the very best care to our ‘treasured’ patients on the ‘Treasure Coast’. Our commitment to the most up to date patient care improves our patients lives. They can ‘see’ everyday.
Dr. Ronald Frenkel. M.D., F.A.C.S., F.I.C.S., Founder.
THE NOT-FOR-PROFIT 501(C)(3) EYE RESEARCH FOUNDATION (ERF) AT EAST FLORIDA EYE INSTITUTE EXEMPLIFIES OUR COMMITMENT TO ADVANCING THE DIAGNOSIS, PREVENTION, AND TREATMENT OF EYE DISEASE THROUGH OUR GROUNDBREAKING RESEARCH. BELOW, OUR VISION RESEARCH CENTERS IN STUART AND PORT ST. LUCIE HAVE PROVIDED OPHTALMOLOGY ARTICLES ON THE CLINICAL RESEARCH THAT HAS BEEN CONDUCTED ON EYE DISEASES.